Andrew W. Lo, PhD

Andrew W. Lo, PhD is a Visiting Member at the Ellison Medical Institute. Professor Lo is collaborating with the Institute to develop data-driven and sustainable approaches to drug pricing.

He is the Charles E. and Susan T. Harris Professor at the MIT Sloan School of Management, director of MIT’s Laboratory for Financial Engineering, and principal investigator at MIT’s Computer Science and Artificial Intelligence Laboratory. His healthcare-related research interests include new financial engineering tools and business models for drug and device development and healthcare delivery, especially for rare and ultra-rare diseases. He also focuses on statistical methods for incorporating patient preferences into the drug approval process, predicting clinical trial outcomes via machine learning techniques, and novel reimbursement models for creating a robust gene and cell therapy ecosystem. His publications can be accessed at alo.mit.edu.

He is a co-founder and director of BridgeBio Pharma and Uncommon Cures; a director of GCAR, n-Lorem, and Vesalius; a co-founder and chairman of QLS Advisors; a co-founder of Quantile Health; and a member of the advisory board to the American Cancer Society’s BrightEdge Impact Fund, the AACR, and several biotech companies. His awards include Guggenheim and Sloan Fellowships; the Paul A. Samuelson Award; the Eugene Fama Prize; the IAFE-SunGard Financial Engineer of the Year; the Global Association of Risk Professionals Risk Manager of the Year; one of TIME’s “100 most influential people in the world”; and awards for teaching excellence from both Wharton and MIT. Dr. Lo received his B.A. in economics from Yale University and his A.M. and Ph.D. in economics from Harvard University.